|
業務類別
|
Biotechnology |
|
業務概覽
|
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent beingdeveloped for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494. |
| 公司地址
| 4300 El Camino Real, Suite 210, Los Altos, CA, USA, 94022 |
| 電話號碼
| +1 650 351-4495 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.unicycive.com |
| 員工數量
| 23 |
| Dr. Pramod Gupta, M.D. |
Executive Vice President, Pharmaceutical and Business Operations |
美元 468.00K |
30/04/2025 |
| Mr. John W. Townsend |
Chief Financial Officer and Principal Accounting Officer |
-- |
30/04/2025 |
| Dr. Shalabh Gupta, M.D. |
Chief Executive Officer, President and Chairman of the Board |
美元 572.00K |
30/04/2025 |
| Mr. Douglas Jermasek |
Executive Vice President, Corporate Strategy |
美元 363.00K |
30/04/2025 |
|
|
| Dr. Shalabh Gupta, M.D. |
Chief Executive Officer, President and Chairman of the Board |
30/04/2025 |
| Dr. Sandeep Laumas, M.D. |
Independent Director |
30/04/2025 |
| Dr. Gaurav Aggarwal, M.D. |
Independent Director |
30/04/2025 |
| Dr. Saraswati Kenkare-Mitra, PhD |
Independent Director |
30/04/2025 |
|
|
|
|
